UK-based healthcare company Haleon has announced a national voluntary recall of Robitussin cough syrup in the US due to microbial contamination.
In a statement on Wednesday, Haleon recalled eight batches of Robitusin Honey CF Max Day Adult and Robitusin Honey CF Max Night Time Adult that had expiration dates from October 2025 to June 2026.
The company said it has not received any reports of adverse events related to the recall.
Robitussin is promoted as a product that soothes sore throats and relieves cough and flu symptoms.
Haleon said immunocompromised people who use the product run the risk of serious or life-threatening adverse events, such as fungemia (the presence of fungi or yeast in the blood).
Symptoms of fungemia include Chronic fatigue, severe confusion, persistent lesions or wounds that do not heal, abnormal and irregular discharge, sweating and itching.
If the product is used by someone with a weakened immune system, it can also cause a disseminated fungal infection, where the fungus can spread throughout the body and cause problems. include Skin ulcers, abscesses, fever, bone lesions or meningitis.
Although life-threatening infections are unlikely for people who are not immunocompromised, Haleon said, “We cannot completely rule out the occurrence of infections that may require medical intervention.” Stated.
The company said it has directly notified distributors and customers and instructed them to return all recalled products. You can contact Haleon's consumer relations team at +1-800-245-1040 or by email at [email protected].
The company added that the recall is being conducted with the knowledge of the Food and Drug Administration.
Since January, at least 4 drug recalls In the U.S., these include lubricant eye drops, various IV bags, Zenzedi tablets or dextroamphetamine sulfate tablets, according to the FDA. Reasons for the recall include concerns about the safety of the device or drug, the possibility of a super-potent drug, or mislabeling on the packaging.
